Abbott Laboratories (ABT)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $187.95B
Last updated: Nov 17, 2026 at 11:05 AM ET
Abbott Laboratories (ABT) Stock Forecast
Analysts expect Abbott Laboratories (ABT) to earn $5.52 per share in the fiscal year ending Dec 31, 2026, on revenue of $49.95B. Of 28 analysts, 23 rate the stock Buy or Strong Buy, 5 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 10 estimates for the fiscal year ending Dec 31, 2026 were revised up and 13 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 82% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 17.9% |
| Buy | 18 | 64.3% |
| Hold | 5 | 17.9% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 28
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 7.6% and revenue estimates rise 7.1%.
- Fiscal year ending Dec 31, 2026
- $5.52
- EPS consensus, revenue $49.95B
- Fiscal year ending Dec 31, 2027
- $5.94
- EPS consensus, revenue $53.50B
- Next report
- Jan 20, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $5.52 | $5.49 to $5.54 | 27 | $49.95B | $49.11B to $50.14B | 25 |
| Dec 31, 2027 | $5.94 | $5.89 to $6.08 | 27 | $53.50B | $51.42B to $54.77B | 27 |
Quarterly Estimates
The EPS consensus falls from $1.65 for the quarter ending Dec 31, 2026 to $1.23 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.65 | $1.60 to $1.73 | 27 | $13.35B | $12.88B to $14.05B | 27 |
| Mar 31, 2027 | $1.23 | $1.20 to $1.28 | 18 | $12.57B | $12.43B to $12.73B | 17 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 12 upward and 50 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 10 | 13 |
| Fiscal year ending Dec 31, 2027 | 1 | 24 |
| Quarter ending Mar 31, 2027 | 1 | 13 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $5.52 | $5.52 | $5.52 | $5.52 | $5.52 | 0.0% |
| Fiscal year ending Dec 31, 2027 | $5.94 | $5.94 | $6.06 | $6.07 | $6.06 | -2.1% |
| Quarter ending Mar 31, 2027 | $1.23 | $1.23 | $1.29 | $1.29 | $1.29 | -4.4% |
Frequently Asked Questions About ABT
What is the ABT stock forecast?
Consensus analyst estimates put Abbott Laboratories's EPS at $5.52 for the fiscal year ending Dec 31, 2026, on revenue of $49.95B. The consensus rating from 28 analysts is Buy.
How do analysts rate ABT stock?
Of 28 analysts covering Abbott Laboratories, 5 rate it Strong Buy, 18 Buy, 5 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ABT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $5.52, with estimates from $5.49 to $5.54 from 27 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $5.94, with estimates from $5.89 to $6.08 from 27 analysts.
What revenue do analysts expect from Abbott Laboratories next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $49.95B, with estimates from $49.11B to $50.14B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $53.50B, with estimates from $51.42B to $54.77B.
How many analysts cover ABT?
28 analysts rate Abbott Laboratories stock, and 27 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ABT pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts